Skip to content
value.today
PAVmed Inc. logo

PAVmed Inc.

PAVM
$16 Mmarket cap on Oct 30, 2026-52.3% since Jan 2024
Compare
World rank
#24,987
Revenue
—
For year ending December-2025
Net income
$0 M
SEC filing
Employees
41
As of March 27, 2026
SEC filing

PAVmed Inc. in brief

PAVmed Inc. is a listed company in the Medical Devices industry, based in New York, New York, USA. Its market value was $16 M on 30 October 2026, which makes it the 24,987th largest listed company in the world and the 4,207th largest in the USA on this site. It employs about 41 people and Lishan Aklog is its chief executive. Its shares trade under the symbol PAVM (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About PAVmed Inc.

PAVmed is a diversified commercial-stage life sciences company operating in the medical device, diagnostics, and digital health sectors. It operates through multiple independently financed subsidiaries under a shared services model. The Company’s strategy is to advance and commercialize innovative healthcare technologies through its subsidiaries while maintaining flexibility to structure financing at either the PAVmed level or within its subsidiaries.

The Company’s subsidiaries include Lucid Diagnostics, a commercial-stage cancer prevention medical diagnostics company that markets the EsoGuard® Esophageal DNA Test and EsoCheck® Esophageal Cell Collection Device, of which the Company is the largest voting stockholder, and Veris Health, a majority-owned digital health company focused on improving personalized cancer care during treatment and throughout survivorship through digital health tools and the development of an implantable physiological monitor designed to interface with the Veris Cancer Care Platform.

From the company's annual report filed with the US SEC: read the report

PAVmed Inc. timeline

4 events, 2014–2024
  1. 2014
  2. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  3. 2015
  4. ✎
    Renamed PAVmed Inc.
    Formerly PAXmed Inc..
  5. 2016
  6. 🔔
    Initial public offering on Nasdaq
    Final prospectus filed with the SEC on 29 January 2016; shares registered for exchange trading on 28 January 2016.
  7. 2024
  8. 💰
    Record revenue of $3 million
    FY2024, the highest of the 4 years on record.

Events of PAVmed Inc. from SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$49 M$98 M$147 M$195 M2020202120222023202420252026

World rank over time

▼ down 2,687 places since 2020
2020-01-01: #22316#22,31620202021-01-01: #17366#17,36620212022-01-07: #19472#19,47220222022-12-25: #25574#25,57420222023-07-30: #26423#26,42320232024-01-05: #27033#27,03320242026-03-08: #12326#12,32620262026-08-01: #20188#20,18820262026-10-13: #24145#24,14520262026-10-30: #25003#25,0032026

Rank in USA: #4,174 (Jan 2020) · #3,561 (Jan 2021) · #3,935 (Jan 2022) · #4,836 (Dec 2022) · #4,882 (Jul 2023) · #4,232 (Jan 2024) · #2,331 (Mar 2026) · #3,809 (Aug 2026) · #4,102 (Oct 2026) · #4,209 (Oct 2026)

Key ratios

market cap and latest results
P/E ratio
39.4×
Price / sales
—
Price / book
0.5×
Free cash flow yield
-33.3%
Net margin
—
Operating margin
—
Return on equity
1.2%
Liabilities / assets
42.5%
Revenue growth
+20.0%
R&D / revenue
197.7%
Profit per employee
$10 K

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2018: revenue —, net income $-18M—FY18Fiscal year ending Dec 2019: revenue —, net income $-16M—FY19Fiscal year ending Dec 2020: revenue —, net income $-34M—FY20Fiscal year ending Dec 2021: revenue $1M, net income $-50M$1MFY21Fiscal year ending Dec 2022: revenue $0M, net income $-89M$0MFY22Fiscal year ending Dec 2023: revenue $3M, net income $-64M$3MFY23Fiscal year ending Dec 2024: revenue $3M, net income $40M$3MFY24Fiscal year ending Dec 2025: revenue —, net income $0M—FY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025——$-22M$0M—
Dec 2024$3M+20.0%$-44M$40M1326.3%
Dec 2023$3M+557.9%$-69M$-64M-2567.2%
Dec 2022$0M-24.0%$-91M$-89M-23415.8%
Dec 2021$1M—$-54M$-50M-10070.0%
Dec 2020——$-23M$-34M—
Dec 2019——$-14M$-16M—
Dec 2018——$-11M$-18M—

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$-5M$0M$-5M$-5.63—
Dec 2024$-34M$0M$-34M$14.90—
Dec 2023$-52M$0M$-52M$-9.16—
Dec 2022$-71M$2M$-73M$-15.03—
Dec 2021$-41M$1M$-42M$-0.65—
Dec 2020$-22M$0M$-22M$-0.72—
Dec 2019$-13M$0M$-13M$-0.54—
Dec 2018$-9M$0M$-9M$-0.81—

Quarterly results

USD · three months to · source: SEC filings
RevenueNet income
Three months to Sep 2024: revenue $1M, net income $64M$1MSep ’24Three months to Dec 2024 (from the annual report): revenue —, net income $1M—Dec ’24Three months to Mar 2025: revenue $0M, net income $19M$0MMar ’25Three months to Jun 2025: revenue $0M, net income $-12M$0MJun ’25Three months to Sep 2025: revenue $0M, net income $-5M$0MSep ’25Three months to Dec 2025 (from the annual report): revenue —, net income $-1M—Dec ’25Three months to Mar 2026: revenue $0M, net income $-0M$0MMar ’26Three months to Jun 2026: revenue $0M, net income $-5M$0MJun ’26

Latest quarter to Jun 2026: revenue $0M (+200.0% on a year earlier), net income $-5M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Jun 2026.

SEC filings

Official filings of PAVmed Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
—
Operating income
$-22 M
Net income
$0 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$39 M
Total liabilities
$17 M
Total equity
$34 M

As of December-2025

Top 24 institutional investors in PAVmed Inc.#

As of Sep 30, 2026
24 institutions held 963,934 shares (about 12.1% of the shares outstanding) on Sep 30, 2026. The ten largest hold 12.1%. Source: SEC Form 13F filings, filed through Nov 17, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 24 largest institutional investors in PAVmed Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
1Two Seas Capital LP461,5390 (0.00%)5.77%$2 MOct 6, 2026
2First Manhattan Co. LLC.333,959+1,048 (+0.31%)4.18%$1 MNov 16, 2026
3Vanguard Capital Management LLC63,207+1,603 (+2.60%)0.79%$0 MNov 13, 2026
4Geode Capital Management, LLC29,466-7,212 (-19.66%)0.37%$0 MNov 6, 2026
5Citadel Advisors LLC29,095New0.36%$0 MNov 16, 2026
6Vanguard Fiduciary Trust Co25,6050 (0.00%)0.32%$0 MNov 13, 2026
7BlackRock, Inc.15,544-1,548 (-9.06%)0.19%$0 MNov 13, 2026
8Pinnacle Financial Group, Inc.4,700—0.06%$0 MNov 16, 2026
9Parkside Financial Bank & Trust246New0.00%$0 MOct 27, 2026
10Royal Bank Of Canada216+215 (+21500.00%)0.00%$0 MNov 16, 2026
11Morgan Stanley160-3 (-1.84%)0.00%$0 MNov 13, 2026
12SBI Securities Co., Ltd.670 (0.00%)0.00%$0 MOct 22, 2026
13UBS Group AG51-6 (-10.53%)0.00%$0 MNov 10, 2026
14Wells Fargo & Company/mn450 (0.00%)0.00%$0 MNov 16, 2026
15Citigroup Inc9New0.00%$0 MNov 4, 2026
16Allworth Financial LP6+1 (+20.00%)0.00%$0 MNov 17, 2026
17Osaic Holdings, Inc.40 (0.00%)0.00%$0 MNov 12, 2026
18Strategic Financial Concepts, LLC4New0.00%$0 MNov 16, 2026
19Federation des caisses Desjardins du Quebec40 (0.00%)0.00%$0 MNov 16, 2026
20Steward Partners Investment Advisory, LLC20 (0.00%)0.00%$0 MNov 13, 2026
21BFC Planning, Inc.20 (0.00%)0.00%$0 MNov 13, 2026
22Jones Financial Companies Lllp10 (0.00%)0.00%$0 MNov 13, 2026
23Foresight Capital Management Advisors, Inc.1New0.00%$0 MOct 27, 2026
24Caitong International Asset Management Co., Ltd10 (0.00%)0.00%$0 MOct 29, 2026

Mutual funds holding PAVmed Inc.#

7 funds hold shares worth $0 M (about 1.0% of the company). Since their previous reports 6 added shares and 0 sold, buying $0 M net.
Mutual funds holding PAVmed Inc.
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc.57,879$0 M0.72%<0.01%+878%Jun 30, 2026
🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors13,795$0 M0.17%<0.01%newJun 30, 2026
🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC6,189$0 M0.08%<0.01%+10%May 31, 2026
🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC1,217$0 M0.02%<0.01%+74%May 31, 2026
🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC881$0 M0.01%<0.01%newJun 30, 2026
🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC262$0 M<0.01%<0.01%no changeMay 31, 2026
🇺🇸 Total Stock Market Index TrustJohn Hancock Variable Trust Advisers LLC226$0 M<0.01%<0.01%newJun 30, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jun 30, 2026. The 7 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at PAVmed Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$0
0 purchases, 0 insiders
Sold, 12 months
$0
0 sales, 0 insiders
Net, 12 months
$0
open market only
Insiders on file
19
since
PAVmed Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Victoria Tou-ho LeeChief Medical OfficerGrant or award+70,000——71,666Form 4
filed Lishan AklogChairman and CEO, DirectorGrant or award+350,000——357,614Form 4
filed Debra WhiteDirectorGrant or award+13,930——21,097Form 4
filed Michael Adam GordonGeneral CounselGrant or award+110,000——115,000Form 4
filed Michael J. GlennonDirectorGrant or award+13,930——21,653Form 4
filed Ronald M. SparksDirectorGrant or award+13,930——21,097Form 4
filed Timothy E. BaxterDirectorGrant or award+13,930——21,097Form 4
filed Shaun O'NeilChief Operating OfficerGrant or award+110,000——115,598Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: PAVmed Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
12,812
1.4% of shares · 1.04 days to cover
Buybacks, Q4 2019
$0M
Q4 2019
Shares sold short, last 24 reportsAll stocks →
PAVmed Inc. share buybacks by quarter
Buybacks, quarterFiscalSpent
Q4 2019Q4 2019$0M

Trading halts

  • 2026-07-23 15:21 UTC, code LUDP, resumed 15:36 UTC
  • 2026-07-16 13:40 UTC, code LUDP, resumed 13:45 UTC
  • 2026-06-18 19:53 UTC, code LUDP, resumed 20:00 UTC
  • 2026-02-02 14:55 UTC, code LUDP, resumed 15:00 UTC
  • 2026-02-02 14:43 UTC, code LUDP, resumed 14:53 UTC

Fails to deliver

  • : 1 shares at $1.97
  • : 233 shares at $2.29
  • : 1 shares at $2.17
  • : 15 shares at $2.05
  • : 107 shares at $2.69

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

PAVmed Inc. scorecard#

Passes 4 of the 12 checks that could be worked out: strongest in profitability (1 of 3), weakest in valuation (1 of 4). Fiscal year 2025; market cap of Oct 30, 2026.

  • Valuation1 of 4
    • ✗P/E below its peers' median39.4×P/E 39.4× against Medical Devices's median of 24.1×.
    • ✓Price to book below its peers' median0.5×Price to book 0.5× against Medical Devices's median of 2.5×.
    • –Price to sales below its peers' medianNo Price to sales on file.
    • ✗Free cash flow yield above 5%-33.3%Free cash flow is -33.3% of the market value.
    • ✗Earnings yield above the 10-year Treasury yield2.5%Earnings yield 2.5% against the 10-year Treasury's 5.15% on 2026-11-13.
    • –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
  • Growth1 of 2
    • –Revenue grew in the newest yearRevenue of the year before is not on file.
    • –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
    • –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
    • ✗Earnings per share grew in the newest year-5.63 vs 14.90Diluted EPS -5.63 in fiscal 2025 against 14.90 the year before (report's currency).
    • ✓Net income higher than five years earlier$0 M$0 M in fiscal 2025 against -$34 M in 2020.
    • –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
  • Profitability1 of 3
    • ✓Profitable in the newest year$0 MNet income $0 M in fiscal 2025.
    • ✗Profitable in each of the last five years2 of 5Profitable in 2 of the five years to fiscal 2025.
    • –Operating margin above its peers' medianNo operating margin on file.
    • ✗Return on equity above 15%2.5%2.5% in fiscal 2025.
    • –Return on invested capital above 10%No return on invested capital on file.
    • –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
  • Financial health0 of 2
    • ✗Short-term assets cover short-term liabilities0.2×Current ratio 0.17 at the end of fiscal 2025.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
    • –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
  • Shareholder returns1 of 1
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • ✓Share count up no more than 2% in a year-69.2%Diluted shares down 69.2% in fiscal 2025.
    • –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
    • –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.

Worked out from the statements as filed (sec), the medians of Medical Devices, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

PAVmed Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

PAVmed Inc.: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020FY 2019to Dec 31, 2019FY 2018to Dec 31, 2018FY 2017to Dec 31, 2017FY 2016to Dec 31, 2016
Income statement
Revenue0.13.02.50.40.5—————
Cost of revenue0.24.86.43.60.6—————
Gross profit————−0.1—————
Research and development4.55.91425r20116.6r4.32.6r1.7
Selling and marketing0.91218198.92.8————
General and administrative16253141r25r9.6r7.7r6.35.4r3.9
Operating expenses————542314r118.05.7
Total costs and expenses22477191r55—————
Operating income−22−44−69−91r−54−23−14r−11−8.0−5.7
Interest and finance income0.00.3————————
Interest expense and finance costs0.00.00.61.3r—0.1r0.0r2.40.7—
Other non-operating income (expense)1973−10−12r−1.7−13−3.0r−7.6−1.5—
Income before tax−2.528−79−103−56−36−17r−18−9.5−5.7
Income tax00————————
Net income including minority interests−2.528−79−103−56−36−17r−18r——
Minority interests' share of net income−2.9−11−15−14−5.8−1.6−0.8r−0.2——
Net income attributable to shareholders0.440−64−89−50−34−16r−18−9.5−5.7
Earnings per share, basic-5.6399.15r-9.16-15.03r-0.65-0.72-0.54-0.81-0.71-0.44
Earnings per share, diluted-5.6314.90r-9.16-15.03-0.65-0.72-0.54-0.81-0.71-0.44
Shares, weighted average (basic)0.70.3r7.25.9r78—————
Shares, weighted average (diluted)0.72.2r7.25.9784730221313
Balance sheet
Cash and cash equivalents1.51.2204077176.2r8.21.50.6
Receivables0.00.00.10.00.2—————
Inventory——0.30.1——————
Other current assets1.01.04.54.1r5.21.70.3r0.20.10.2
Current assets2.62.2244483196.5r8.51.60.7
Property, plant and equipment0.10.21.82.51.60.1—0.00.00.0
Right-of-use (leased) assets2.02.54.33.0——————
Other intangible assets——1.43.42.0—————
Investments in associates3426————————
Total assets3931335487207.2r8.51.60.9
Accounts payable0.70.71.82.73.33.02.4r1.70.9r0.9
Current liabilities153554417.6—12r112.51.2
Lease liabilities (non-current)1.72.23.01.8——————
Total liabilities173857437.62012r114.51.2
Retained earnings−259−255−294−228−139−88−54r−37−18−7.7
Shareholders' equity34−2.5−54−9.7621.9−3.8r−2.3−2.8−0.3
Minority interests−12−4.5302118−2.4−0.8r−0.2——
Total equity22−7.0−241179−0.5−4.6r−2.5r−2.8−0.3
Total liabilities and equity3931335487207.2r8.51.60.9
Shares outstanding0.90.4r8.66.3r866440r271513
Cash-flow statement
Depreciation and amortization0.11.22.92.50.2—————
Share-based compensation1.76.41120152.01.6r1.21.00.7
Cash from operating activities−5.2−34−52−71−41−22−13r−8.8−6.6−4.5
Capital expenditure−0.0−0.1−0.2−1.5−1.5−0.1−0.0r−0.0−0.0−0.0
Acquisitions, net of cash acquired———−3.2−2.2—————
Cash from investing activities−0.0−160.8−4.7−3.7−0.1−0.0r−0.0−0.0−0.0
Debt issued————————7.5—
Debt repaid——————−6.1———
Shares issued—1.61.50.155165.4r———
Shares bought back——————−0.1———
Cash from financing activities5.63131381043311r167.64.3
Change in cash0.4−18−20−386011−2.0r6.70.9−0.2
Report10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Jun 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

Executive pay at PAVmed Inc.#

From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.

CEO total pay, fiscal 2025
$1.0 M
Lishan Aklog, M.D
Other top executives, average
$596 K
the CEO earned 1.7× this
$100 invested is now
$3
PAVmed Inc.: executive pay by fiscal year
Fiscal yearCEO total payActually paidOther executives, average$100 invested
2025Lishan Aklog, M.D$1.0 M$992 K$596 K$3
2024Lishan Aklog, M.D$1.4 M$798 K$1.1 M$2
2023Lishan Aklog, M.D$953 K$883 K$627 K$11

Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025

Events at PAVmed Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

Warning signs in the last three years

  • Auditor changedFiling
  • Delisting noticeFiling
  • Delisting noticeFiling

Delisting notice 2 · Auditor changed 1 · Directors and officers 3 · Material agreement 5 · Agreement ended 1 · New debt 1 · Unregistered share sale 4 · Shareholder rights changed 5 · Bylaws or fiscal year changed 5 · Shareholder vote 5 · Results announced 7

PAVmed Inc.: events reported to the SEC
FiledWhat happenedFiling
Material agreementShareholder rights changed8-K
Material agreement8-K
Results announced8-K
Directors and officersShareholder vote8-K
Results announced8-K
Results announced8-K
Directors and officersBylaws or fiscal year changedShareholder vote8-K
Material agreementAgreement endedNew debtUnregistered share saleShareholder rights changedBylaws or fiscal year changed8-K
Shareholder rights changedBylaws or fiscal year changed8-K
Shareholder vote8-K
Results announced8-K
Results announced8-K
Material agreement8-K
Directors and officersShareholder vote8-K
Results announced8-K
Auditor changed8-K
Material agreement8-K
Results announced8-K
Unregistered share sale8-K
Delisting noticeUnregistered share saleShareholder rights changed8-K
Delisting noticeUnregistered share saleShareholder rights changedBylaws or fiscal year changed8-K
Bylaws or fiscal year changedShareholder vote8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Oct 22, 2026

Acquisitions and funding#

Private share sales · funding history

Private share sales of PAVmed Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Feb 2026$30 MPrivate placement after listing$10 to $50 million14equity, optionsSEC
Jan 2025$3 MPrivate placement after listing$2 to $10 million1equitySEC
Aug 2020$8 MPrivate placement after listing$2 to $10 million1debt, optionsSEC
Apr 2020$4 MPrivate placement after listing$2 to $10 million1debt, optionsSEC
Nov 2019$14 MPrivate placement after listing$10 to $50 million2debt, optionsSEC
Dec 2018$8 MPrivate placement after listing$2 to $10 million1debt, optionsSEC
Jan 2017$2 MPrivate placement after listingUnder $2 million13equity, debtSEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

H-1B hiring at PAVmed Inc.#

2 labor condition applications certified in fiscal 2026 for 2 positions, at a median wage of $120 K a year.

Certified, FY2026
2
#1,564 among companies on value.today
Worker positions
2
Median wage offered
$120 K
a year, full-time
Applications filed
2
PAVmed Inc.: most frequent H-1B job titles in fiscal 2026
Job titlePositionsMedian wage offered
Manager, Clinical Research Data [00099460]Clinical Research Coordinators1$110 K
Senior Manufacturing Engineer [00111112]Manufacturing Engineers1$130 K

Where: New York, NY 2

PAVmed Inc.: labor condition applications by fiscal year
Fiscal yearCertifiedPositionsMedian wageFiled
FY202622$120 K2
FY202511$112 K1
FY202411$110 K1
FY202222$80 K2
FY202111$125 K1

Source: US Department of Labor, LCA disclosure data. An application is not a visa: USCIS decides each petition later, and the yearly lottery limits new H-1B visas. Filed as PAVmed Inc.

How PAVmed Inc. compares in Medical Devices

  • Market cap$16 M · higher than 9% of 142
  • Revenue growth20.0% · higher than 74% of 104
  • P/E ratio39.4× · lower than 33% of 47
  • Price / book0.5× · lower than 97% of 99
  • FCF yield-33.3% · higher than 24% of 76

Peer comparison · Medical Devices

CompanyMarket capP/ENet marginRev. growth
PAVmed Inc.🇺🇸$16 M39.4×—+20.0%
Abbott Laboratories🇺🇸$181.1 B38.5×9.8%+5.7%
Medtronic plc🇺🇸$121.2 B23.2×13.9%+8.4%
Stryker Corporation🇺🇸$116.5 B32.2×13.8%+11.2%
Boston Scientific Corporation🇺🇸$66.2 B18.9×16.6%+19.9%
Edwards Lifesciences Corporation🇺🇸$52.8 B51.7×15.3%+11.6%
Shenzhen Mindray Bio-Medical Electronics Co., Ltd.🇨🇳$27.8 B23.6×24.4%—
STERIS plc🇮🇪$20.4 B24.6×13.4%+8.7%
Zimmer Biomet Holdings, Inc.🇺🇸$18.2 B23.8×8.9%+7.2%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Oct 30, 2026
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Employees:
As of March 27, 2026
Profile updated:
Nov 20, 2026

Figures from Market data, SEC filing, value.today research, SEC annual report, GLEIF register; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at PAVmed Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show PAVmed Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about PAVmed Inc.? Suggest a correction